摘要
目的:探讨乳腺癌中雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体-2(CerbB-2)癌基因表达及其与乳腺癌临床病理的相关性。方法:采用常规免疫组化法检测213例临床病理资料完整的乳腺癌组织中的CerbB-2、ER和PR表达。结果:CerbB-2、ER和PR的阳性率分别为43.2%(92/213)、54.0%(115/213)、50.7%(108/213)。CerbB-2的表达与肿瘤大小、组织学分级、淋巴结转移和临床分期呈正相关(P<0.05),与病理类型无关,在ER和PR均阳性组的表达低于二者均阴性组的表达(P<0.05);ER和PR的表达与患者的肿瘤大小、病理类型无关。结论:CerbB-2、ER、PR表达与乳腺癌的发生发展有关,CerbB-2、ER、PR的测定是判断乳腺癌预后的重要指标,可以为临床制定乳腺癌的综合治疗方案提供重要依据。
Objective：To evaluate the expressions of CerbB-2,ER and PR in human breast carcinoma and their relations with clinicopathological features.Methods：We used immunohistochemical method to detect the expression of CerbB-2,ER and PR in 213 cases of breast cancer.Results：The positive rates of expression of ER,PR and CerbB-2 in breast cancers were 43.2%,54.0% and 50.7% respectively.The expression of CerbB-2 was positively correlated with tumor size,histological grade,lymph node metastasis and clinical stages（P0.05）,no significant association of expression of CerbB-2 with histological types was noted（P0.05）.The expression of CerbB-2 in the positive group with the expression of ER,PR was lower than that in the negative group（P0.05）.No significant association of expression of ER and PR with tumor diameter and histological types was noted（P0.05）.Conclusion：ER,PR and CerbB-2 are concerned with the occurrence and development of breast cancer.Testing ER,PR and CerbB-2 expression is important indicator to diagnose breast cancer,which may provide the important basis for formulating the comprehensive therapeutic regimen of breast cancer.
出处
《现代医药卫生》
2011年第2期190-192,共3页
Journal of Modern Medicine & Health
